Scope of U.S. Patent 8,246,980 (TDS microreservoir self-adhesive matrix for free-base fentanyl or oxybutynin): claim boundaries, patent estate leverage, and generic design-around map

United States Patent 8,246,980 claims a specific transdermal delivery system (TDS) architecture: a self-adhesive matrix embedding microreservoirs filled with an amine-functional drug in free base form, where the matrix is permeable to the free base and substantially impermeable to the protonated form, with defined microreservoir size/number and optional crystallization inhibitors, specific silicone pressure-sensitive adhesive (PSA) chemistries, and carrier layers (protective foil, inert backing).

The claim set is narrow on the “free base plus selective permeability” construct and even narrower on microreservoir geometry and counts. At the same time, it is broad enough to read on multiple delivery formulations so long as the drug remains in free base form in reservoirs and the matrix exhibits the claimed permeability asymmetry. Below is a structured claim-by-claim scope read and the practical patent landscape implications for infringement risk and design-around.

What is the scope of US Patent 8,246,980 transdermal delivery system claims?

Core invention in plain terms

A TDS with:
1. a self-adhesive matrix (optionally silicone PSA based),
2. microreservoirs inside the matrix,
3. microreservoirs contain an amine-functional drug in free base form,
4. microreservoir diameter is less than matrix thickness (with dependent limits),
5. matrix is permeable to free base drug but substantially impermeable to protonated drug.

This is an IP “double filter”:

the drug form (free base vs protonated),
the transport behavior of the matrix (selective permeability).

What does “amine-functional drug in free base form” constrain?

Independent claim 1 limits the drug to fentanyl or oxybutynin (free base form). Dependent claim 17 adds a broader genus for aminotetralin compounds, but still tied to free base and the selective permeability requirement.

Key infringement trigger: In an accused product, the reservoir contents and/or delivered drug species must be treated as “free base form.” If the product’s drug is fully/primarily protonated due to formulation pH, salt formation, or microenvironment, the “substantially impermeable to protonated form” limitation becomes difficult to satisfy.

What does “substantially impermeable to protonated form” imply for infringement?

This is a functional limitation. In practice it means the matrix polymer/PSA system is engineered so that protonated drug does not permeate across the matrix efficiently, while free base does.

Claim consequence:

A competitor can attempt to argue their matrix does not show the claimed impermeability behavior to protonated species.
In litigation, this functional limitation often turns on expert testing and formulation characterization at the TDS/skin interface and within the matrix.

Does claim 1 require drug to be “in reservoirs” and not just dispersed?

Yes. The microreservoirs “contain” the free base drug; reservoirs must exist as discrete compartments inside the matrix.

Which fentanyl and oxybutynin free base transdermal systems fall within independent claim 1?

Answer (claim 1 boundary conditions) A product is within claim 1 if all are true:

It has a self-adhesive matrix.
The matrix contains microreservoirs embedded inside it.
The microreservoirs contain an amine-functional drug in free base form where drug is fentanyl or oxybutynin.
The maximum microreservoir diameter is less than the thickness of the self-adhesive matrix.
The self-adhesive matrix is permeable to the free base form.
The self-adhesive matrix is substantially impermeable to the protonated form.

Claim 1 geometry limitation: “maximum diameter less than thickness”

This is a packaging-style dimensional constraint. If a competitor uses microreservoirs larger than or equal to matrix thickness, they exit claim 1 (assuming “maximum diameter” meets the accused structure).

Claim 1 functional constraint: selective permeability

Even if microreservoirs and free-base content exist, the transport selectivity must match.

How do dependent claims narrow microreservoir size, count, and material composition?

Microreservoir size (dependent)

Claim 2: mean diameter 0.5 to 20 μm.
Claim 10: maximum diameter ≤ 35 μm.
Claim 1 already requires max diameter < matrix thickness.

A design that uses microreservoirs outside 0.5–20 μm (mean) or >35 μm (max) avoids specific dependent claim coverage, but still could infringe claim 1 if the “max < thickness” and selective permeability + free base remain satisfied.

Microreservoir density (dependent)

Claim 9 and Claim 15 (same language): 103 to 109 microreservoirs per cm² of matrix surface.

Coverage implication:

If an accused device uses a substantially different reservoir density, it may fall outside these dependent claims.
It may still meet independent claim 1 if density is not a required limitation there. So density affects claim layering, not necessarily independent claim 1.

Matrix composition: silica exclusion (dependent)

Claim 3: matrix is free of silica particles that can absorb salts of the amine drug at the TDS/skin interface.

This is a targeted exclusion aimed at preventing a mechanism that would promote protonated/salt accumulation at the interface. If the competitor uses silica particles that bind salts, they could argue non-infringement of claim 3, but claim 1 may still be at issue depending on whether silica changes transport selectivity.

PSA chemistries (dependent)

Claim 4: matrix comprises a silicone pressure sensitive adhesive.
Claim 5: matrix comprises two or more silicone PSAs.
Claim 6: silicone PSA is a blend of:
- high tack PSA (polysiloxane with resin),
- medium tack PSA (polysiloxane with resin).

These dependents narrow to silicone PSA systems. A non-silicone PSA system may avoid claims 4–6 but could still implicate claim 1 if it satisfies the selective permeability and free-base microreservoir structure.

Crystallization inhibitor (dependent)

Claim 7: microreservoirs further contain at least one crystallization inhibitor including:
- soluble polyvinylpyrrolidone (PVP),
- PVP/vinyl acetate copolymer,
- polyethylene glycol,
- polypropylene glycol,
- glycerol,
- glycerol fatty acid ester,
- copolymer of ethylene/vinyl acetate.
Claim 8: crystallization inhibitor comprises soluble PVP.

Again, these are layering claims. Excluding crystallization inhibitors may avoid claims 7–8 but not necessarily claim 1 unless crystallization inhibitor is required to achieve the claimed permeability selectivity.

What packaging layers are claimed: protective foil and inert backing?

Claim 11: includes a protective foil/sheet removed prior to use.
Claim 12: includes a backing layer.
Claim 13: backing is inert to matrix components.
Claim 16: combines foil + backing + microreservoir count + microreservoir max diameter constraints.

These features likely correspond to conventional patch construction. They are not strictly required by claim 1 but appear in dependent claim claims 11–16. A competitor omitting foil or using a non-inert backing could avoid these dependent layers but still infringe claim 1 if the core TDS architecture is present.

Does claim 14 broaden the polymer description to “semi-permeable polymer”?

Claim 14: self-adhesive matrix comprises a solid or semi-solid semi-permeable polymer.

This is a functional materials category. It can broaden beyond specific silicone PSAs by recasting the matrix as a semi-permeable polymer capable of selective drug transport.

A competitor using a semi-permeable polymer PSA system still risks claim 14 if the matrix meets the stated “semi-permeable” characterization and claim 1 functional permeation asymmetry.

How does claim 17 expand beyond fentanyl/oxybutynin to aminotetralin compounds?

Claim 17: A TDS with:
- self-adhesive matrix and microreservoirs,
- microreservoirs contain an amine-functional drug in free base form selected from aminotetralin compounds,
- same microreservoir diameter rule (max < matrix thickness),
- same selective permeability requirement: matrix permeable to free base, substantially impermeable to protonated form.

Practical scope meaning

Claim 17 is not a generic “any amine drug” claim. It ties the inventive selective-permeability architecture to a particular pharmacophore class (aminotetralins).
For competitive landscape mapping, claim 17 expands the theoretical reach if other aminotetralin free base reservoir systems use the same matrix transport asymmetry.

What is the patent landscape likely to look like around US 8,246,980 given the claim structure?

Based on the claim architecture, the most relevant neighboring IP families are typically:

TDS microreservoir structures (manufacturing, geometry, density, compartmentalization),
free-base vs salt state control within reservoirs,
PSA matrices with selective permeability and interface-binding control (silica/salt absorbents),
crystallization inhibition to keep free base from precipitating or converting,
silicone PSA blends with defined tack profiles.

Business implication: Even if a competitor designs around one dependent limitation (e.g., silica exclusion or PSA type), they can still face infringement under claim 1 if they retain the free-base selective-permeability microreservoir architecture.

Where are the main design-around options for a potential generic or follow-on TDS?

1) Change the drug form in microreservoirs (salt vs free base)

The claims are explicitly “free base form.” A product that uses the drug predominantly as a protonated salt within reservoirs, or introduces a formulation environment that rapidly converts to protonated form before permeation, is the cleanest escape route.

Risk trade:

Turning salts on can change skin permeation and may require new excipient systems.
But as an IP matter, it attacks the core limitation.

2) Eliminate the selective permeability asymmetry

If the matrix is not “substantially impermeable” to protonated drug, claim 1 may not read. This requires formulation change: polymer selection, PSA chemistry, and interface pH microenvironment.

Litigation consequence: Functional limitations increase evidentiary burden and expert disputes, but they are still enforceable.

3) Reengineer microreservoir size and/or packing

Dependent constraints on mean diameter (0.5–20 μm), max diameter (≤35 μm), and density (103–109 per cm²) can be targeted.

Important: These are dependents. If the core claim 1 survives, density/mean diameter changes do not guarantee non-infringement.

4) Remove silica binding mechanism (or replace with non-qualifying particles)

Claim 3 requires silica particles that can absorb salts at the interface to be absent. If a competitor uses silica that absorbs salts, they avoid claim 3 but could still infringe claim 1.

5) Change PSA chemistry

Claims 4–6 narrow silicone PSA use. Switching to non-silicone PSA may avoid these dependents. The core still remains claim 1’s selective permeability structure.

Which competitors are most likely exposed? (inferred from claim scope mechanics)

No reliable mapping to specific companies can be produced from the information provided. A defensible exposure map requires knowing:

the assignee/origin of 8,246,980,
the specific marketed TDS products that use the same free-base microreservoir architecture,
the relevant continuations and divisional filings.

Under the constraints here, only the claim-mechanics exposure can be stated, not the named-company landscape.

How to read infringement risk at the claim level (highest to lowest)

Claim	Main limitation set	Highest risk when product…	Easier non-infringement lever
1 (independent)	free-base fentanyl or oxybutynin + microreservoirs + matrix permeable to free base and substantially impermeable to protonated form + max diameter < matrix thickness + self-adhesive matrix	contains microreservoirs with free base and matrix shows selective permeability	move away from free-base in reservoirs, or eliminate selective permeability asymmetry
2	mean microreservoir diameter 0.5–20 μm	reservoir geometry in that range	change reservoir size distribution
3	silica-free absorber of salts at interface	no qualifying silica binding salts	include silica absorber (but still check claim 1)
4–6	silicone PSA / specific blend	matrix uses silicone PSA blend	use non-silicone PSA and ensure claim 1 compatibility
7–8	crystallization inhibitor types (incl soluble PVP)	reservoirs include specified anti-crystallizers	omit those specific inhibitors
9,15	microreservoir density 103–109 per cm²	reservoir count in that range	change density
10	max diameter ≤35 μm	max reservoir diameter within limit	increase beyond 35 μm (still must be < matrix thickness for claim 1)
11–13,16	foil and inert backing	typical patch packaging layers present	change construction (foil/backing)
14	solid/semi-solid semi-permeable polymer matrix	matrix fits semi-permeable category	choose matrix that is not semi-permeable in claim sense
17	aminotetralin free base architecture	aminotetralin free base microreservoir TDS	swap drug class/formulation

Key Takeaways

U.S. Patent 8,246,980 is anchored on a free-base microreservoir TDS architecture with a matrix transport selectivity limitation: permeable to free base, substantially impermeable to protonated form.
Dependent claims narrow by microreservoir size, microreservoir density, silica absence, silicone PSA composition, and crystallization inhibitors.
Design-around that only changes reservoir count, tack profile, or inclusion of crystallization inhibitors may not avoid infringement of claim 1 if the selective free-base/protonated transport behavior and free-base reservoir condition remain.
The most structurally decisive escape routes target either (a) drug form (free base vs protonated/salt) inside reservoirs, or (b) the selective permeability asymmetry.

FAQs

1) What does “self-adhesive matrix is substantially impermeable to protonated form” mean for testing in litigation?

It is a functional limitation that typically requires expert testing showing reduced permeation of the protonated species relative to free base through the matrix, including evaluation near the TDS/skin interface.

2) If a TDS uses free base fentanyl but non-microreservoir delivery, does it avoid the patent?

If it does not include microreservoirs containing the free base drug embedded within a self-adhesive matrix, it is outside the claimed structure of claim 1 (even if permeation selectivity is present).

3) Does changing PSA from silicone to another polymer avoid infringement?

It can avoid dependent claims tied to silicone PSA (claims 4–6), but it does not avoid claim 1 unless the accused system also fails the selective permeability and free-base microreservoir limitations.

4) Can a product with microreservoirs larger than the matrix thickness escape all claims?

It can escape claim 1 if the “maximum diameter less than the thickness” limitation is not met, but it must also avoid other asserted claim coverage in the patent family (not analyzed here).

5) Are microreservoir density and mean diameter required for infringement of claim 1?

No. Those are dependent limitations in claims 2 and 9/15. Claim 1 requires only that the maximum microreservoir diameter is less than matrix thickness and that the free-base selective permeability architecture exists.

References

United States Patent 8,246,980.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02016864	Jul 30, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	343380	⤷ Start Trial
Australia	2003266252	⤷ Start Trial
Brazil	0313092	⤷ Start Trial
Canada	2490573	⤷ Start Trial
China	100558350	⤷ Start Trial
China	1671365	⤷ Start Trial
Germany	60309329	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,246,980

Summary for Patent: 8,246,980